<i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer

Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling o...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Takahiro Yokose [verfasserIn] Yasuaki Kabe [verfasserIn] Atsushi Matsuda [verfasserIn] Minoru Kitago [verfasserIn] Sachiko Matsuda [verfasserIn] Miwa Hirai [verfasserIn] Tomomi Nakagawa [verfasserIn] Yohei Masugi [verfasserIn] Takako Hishiki [verfasserIn] Yuki Nakamura [verfasserIn] Masahiro Shinoda [verfasserIn] Hiroshi Yagi [verfasserIn] Yuta Abe [verfasserIn] Go Oshima [verfasserIn] Shutaro Hori [verfasserIn] Yutaka Nakano [verfasserIn] Kazufumi Honda [verfasserIn] Ayumi Kashiro [verfasserIn] Chigusa Morizane [verfasserIn] Satoshi Nara [verfasserIn] Shojiro Kikuchi [verfasserIn] Takahiko Shibahara [verfasserIn] Makoto Itonaga [verfasserIn] Masayuki Ono [verfasserIn] Naoko Minegishi [verfasserIn] Seizo Koshiba [verfasserIn] Masayuki Yamamoto [verfasserIn] Atsushi Kuno [verfasserIn] Hiroshi Handa [verfasserIn] Michiie Sakamoto [verfasserIn] Makoto Suematsu [verfasserIn] Yuko Kitagawa [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	extracellular vesicles lectin microarray pancreatic cancer liquid biopsy glycomics

Übergeordnetes Werk:	In: Cancers - MDPI AG, 2010, 12(2020), 9, p 2469
Übergeordnetes Werk:	volume:12 ; year:2020 ; number:9, p 2469

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/cancers12092469

Katalog-ID:	DOAJ041581040

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ041581040
003	DE-627
005	20240412214526.0
007	cr uuu---uuuuu
008	230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/cancers12092469 \|2 doi
035			\|a (DE-627)DOAJ041581040
035			\|a (DE-599)DOAJ002f3f7d7400416893ba4df7bfef8829
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Takahiro Yokose \|e verfasserin \|4 aut
245	1	0	\|a <i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling of extracellular vesicles (EVs) derived from serum (two cohorts including 117 PC patients and 98 normal controls) using lectin microarray. The glyco-candidates of PC-specific EVs were quantified using a high-sensitive exosome-counting system, ExoCounter. An absolute quantification system for altered glycan-containing EVs elevated in PC serum was established. EVs recognized by <i<O</i<-glycan-binding lectins ABA or ACA were identified as candidate markers by lectin microarray. Quantitative analyses using ExoCounter revealed that the ABA- or ACA-positive EVs were significantly increased in the culture of PC cell lines or in the serum of PC patients including carbohydrate antigen 19-9 negative patients with high area under curve values. The elevated numbers of EVs in PC serum returned to normal levels after pancreatectomy. Histological examination confirmed that the tumors stained with ABA/ACA. These specific EVs with <i<O</i<-glycans recognized by ABA/ACA are elevated in PC sera and can act as potential biomarkers in a liquid biopsy for PC patients screening.
650		4	\|a extracellular vesicles
650		4	\|a lectin microarray
650		4	\|a pancreatic cancer
650		4	\|a liquid biopsy
650		4	\|a <i<O</i<-glycan
650		4	\|a glycomics
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Yasuaki Kabe \|e verfasserin \|4 aut
700	0		\|a Atsushi Matsuda \|e verfasserin \|4 aut
700	0		\|a Minoru Kitago \|e verfasserin \|4 aut
700	0		\|a Sachiko Matsuda \|e verfasserin \|4 aut
700	0		\|a Miwa Hirai \|e verfasserin \|4 aut
700	0		\|a Tomomi Nakagawa \|e verfasserin \|4 aut
700	0		\|a Yohei Masugi \|e verfasserin \|4 aut
700	0		\|a Takako Hishiki \|e verfasserin \|4 aut
700	0		\|a Yuki Nakamura \|e verfasserin \|4 aut
700	0		\|a Masahiro Shinoda \|e verfasserin \|4 aut
700	0		\|a Hiroshi Yagi \|e verfasserin \|4 aut
700	0		\|a Yuta Abe \|e verfasserin \|4 aut
700	0		\|a Go Oshima \|e verfasserin \|4 aut
700	0		\|a Shutaro Hori \|e verfasserin \|4 aut
700	0		\|a Yutaka Nakano \|e verfasserin \|4 aut
700	0		\|a Kazufumi Honda \|e verfasserin \|4 aut
700	0		\|a Ayumi Kashiro \|e verfasserin \|4 aut
700	0		\|a Chigusa Morizane \|e verfasserin \|4 aut
700	0		\|a Satoshi Nara \|e verfasserin \|4 aut
700	0		\|a Shojiro Kikuchi \|e verfasserin \|4 aut
700	0		\|a Takahiko Shibahara \|e verfasserin \|4 aut
700	0		\|a Makoto Itonaga \|e verfasserin \|4 aut
700	0		\|a Masayuki Ono \|e verfasserin \|4 aut
700	0		\|a Naoko Minegishi \|e verfasserin \|4 aut
700	0		\|a Seizo Koshiba \|e verfasserin \|4 aut
700	0		\|a Masayuki Yamamoto \|e verfasserin \|4 aut
700	0		\|a Atsushi Kuno \|e verfasserin \|4 aut
700	0		\|a Hiroshi Handa \|e verfasserin \|4 aut
700	0		\|a Michiie Sakamoto \|e verfasserin \|4 aut
700	0		\|a Makoto Suematsu \|e verfasserin \|4 aut
700	0		\|a Yuko Kitagawa \|e verfasserin \|4 aut
773	0	8	\|i In \|t Cancers \|d MDPI AG, 2010 \|g 12(2020), 9, p 2469 \|w (DE-627)614095670 \|w (DE-600)2527080-1 \|x 20726694 \|7 nnns
773	1	8	\|g volume:12 \|g year:2020 \|g number:9, p 2469
856	4	0	\|u https://doi.org/10.3390/cancers12092469 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/002f3f7d7400416893ba4df7bfef8829 \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2072-6694/12/9/2469 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2072-6694 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 12 \|j 2020 \|e 9, p 2469

Indexfelder

author_variant	t y ty y k yk a m am m k mk s m sm m h mh t n tn y m ym t h th y n yn m s ms h y hy y a ya g o go s h sh y n yn k h kh a k ak c m cm s n sn s k sk t s ts m i mi m o mo n m nm s k sk m y my a k ak h h hh m s ms m s ms y k yk
matchkey_str	article:20726694:2020----::ogyaatrdxrcluavsceapcfceumreee
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	10.3390/cancers12092469 doi (DE-627)DOAJ041581040 (DE-599)DOAJ002f3f7d7400416893ba4df7bfef8829 DE-627 ger DE-627 rakwb eng RC254-282 Takahiro Yokose verfasserin aut <i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling of extracellular vesicles (EVs) derived from serum (two cohorts including 117 PC patients and 98 normal controls) using lectin microarray. The glyco-candidates of PC-specific EVs were quantified using a high-sensitive exosome-counting system, ExoCounter. An absolute quantification system for altered glycan-containing EVs elevated in PC serum was established. EVs recognized by <i<O</i<-glycan-binding lectins ABA or ACA were identified as candidate markers by lectin microarray. Quantitative analyses using ExoCounter revealed that the ABA- or ACA-positive EVs were significantly increased in the culture of PC cell lines or in the serum of PC patients including carbohydrate antigen 19-9 negative patients with high area under curve values. The elevated numbers of EVs in PC serum returned to normal levels after pancreatectomy. Histological examination confirmed that the tumors stained with ABA/ACA. These specific EVs with <i<O</i<-glycans recognized by ABA/ACA are elevated in PC sera and can act as potential biomarkers in a liquid biopsy for PC patients screening. extracellular vesicles lectin microarray pancreatic cancer liquid biopsy <i<O</i<-glycan glycomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yasuaki Kabe verfasserin aut Atsushi Matsuda verfasserin aut Minoru Kitago verfasserin aut Sachiko Matsuda verfasserin aut Miwa Hirai verfasserin aut Tomomi Nakagawa verfasserin aut Yohei Masugi verfasserin aut Takako Hishiki verfasserin aut Yuki Nakamura verfasserin aut Masahiro Shinoda verfasserin aut Hiroshi Yagi verfasserin aut Yuta Abe verfasserin aut Go Oshima verfasserin aut Shutaro Hori verfasserin aut Yutaka Nakano verfasserin aut Kazufumi Honda verfasserin aut Ayumi Kashiro verfasserin aut Chigusa Morizane verfasserin aut Satoshi Nara verfasserin aut Shojiro Kikuchi verfasserin aut Takahiko Shibahara verfasserin aut Makoto Itonaga verfasserin aut Masayuki Ono verfasserin aut Naoko Minegishi verfasserin aut Seizo Koshiba verfasserin aut Masayuki Yamamoto verfasserin aut Atsushi Kuno verfasserin aut Hiroshi Handa verfasserin aut Michiie Sakamoto verfasserin aut Makoto Suematsu verfasserin aut Yuko Kitagawa verfasserin aut In Cancers MDPI AG, 2010 12(2020), 9, p 2469 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:12 year:2020 number:9, p 2469 https://doi.org/10.3390/cancers12092469 kostenfrei https://doaj.org/article/002f3f7d7400416893ba4df7bfef8829 kostenfrei https://www.mdpi.com/2072-6694/12/9/2469 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020 9, p 2469
spelling	10.3390/cancers12092469 doi (DE-627)DOAJ041581040 (DE-599)DOAJ002f3f7d7400416893ba4df7bfef8829 DE-627 ger DE-627 rakwb eng RC254-282 Takahiro Yokose verfasserin aut <i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling of extracellular vesicles (EVs) derived from serum (two cohorts including 117 PC patients and 98 normal controls) using lectin microarray. The glyco-candidates of PC-specific EVs were quantified using a high-sensitive exosome-counting system, ExoCounter. An absolute quantification system for altered glycan-containing EVs elevated in PC serum was established. EVs recognized by <i<O</i<-glycan-binding lectins ABA or ACA were identified as candidate markers by lectin microarray. Quantitative analyses using ExoCounter revealed that the ABA- or ACA-positive EVs were significantly increased in the culture of PC cell lines or in the serum of PC patients including carbohydrate antigen 19-9 negative patients with high area under curve values. The elevated numbers of EVs in PC serum returned to normal levels after pancreatectomy. Histological examination confirmed that the tumors stained with ABA/ACA. These specific EVs with <i<O</i<-glycans recognized by ABA/ACA are elevated in PC sera and can act as potential biomarkers in a liquid biopsy for PC patients screening. extracellular vesicles lectin microarray pancreatic cancer liquid biopsy <i<O</i<-glycan glycomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yasuaki Kabe verfasserin aut Atsushi Matsuda verfasserin aut Minoru Kitago verfasserin aut Sachiko Matsuda verfasserin aut Miwa Hirai verfasserin aut Tomomi Nakagawa verfasserin aut Yohei Masugi verfasserin aut Takako Hishiki verfasserin aut Yuki Nakamura verfasserin aut Masahiro Shinoda verfasserin aut Hiroshi Yagi verfasserin aut Yuta Abe verfasserin aut Go Oshima verfasserin aut Shutaro Hori verfasserin aut Yutaka Nakano verfasserin aut Kazufumi Honda verfasserin aut Ayumi Kashiro verfasserin aut Chigusa Morizane verfasserin aut Satoshi Nara verfasserin aut Shojiro Kikuchi verfasserin aut Takahiko Shibahara verfasserin aut Makoto Itonaga verfasserin aut Masayuki Ono verfasserin aut Naoko Minegishi verfasserin aut Seizo Koshiba verfasserin aut Masayuki Yamamoto verfasserin aut Atsushi Kuno verfasserin aut Hiroshi Handa verfasserin aut Michiie Sakamoto verfasserin aut Makoto Suematsu verfasserin aut Yuko Kitagawa verfasserin aut In Cancers MDPI AG, 2010 12(2020), 9, p 2469 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:12 year:2020 number:9, p 2469 https://doi.org/10.3390/cancers12092469 kostenfrei https://doaj.org/article/002f3f7d7400416893ba4df7bfef8829 kostenfrei https://www.mdpi.com/2072-6694/12/9/2469 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020 9, p 2469
allfields_unstemmed	10.3390/cancers12092469 doi (DE-627)DOAJ041581040 (DE-599)DOAJ002f3f7d7400416893ba4df7bfef8829 DE-627 ger DE-627 rakwb eng RC254-282 Takahiro Yokose verfasserin aut <i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling of extracellular vesicles (EVs) derived from serum (two cohorts including 117 PC patients and 98 normal controls) using lectin microarray. The glyco-candidates of PC-specific EVs were quantified using a high-sensitive exosome-counting system, ExoCounter. An absolute quantification system for altered glycan-containing EVs elevated in PC serum was established. EVs recognized by <i<O</i<-glycan-binding lectins ABA or ACA were identified as candidate markers by lectin microarray. Quantitative analyses using ExoCounter revealed that the ABA- or ACA-positive EVs were significantly increased in the culture of PC cell lines or in the serum of PC patients including carbohydrate antigen 19-9 negative patients with high area under curve values. The elevated numbers of EVs in PC serum returned to normal levels after pancreatectomy. Histological examination confirmed that the tumors stained with ABA/ACA. These specific EVs with <i<O</i<-glycans recognized by ABA/ACA are elevated in PC sera and can act as potential biomarkers in a liquid biopsy for PC patients screening. extracellular vesicles lectin microarray pancreatic cancer liquid biopsy <i<O</i<-glycan glycomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yasuaki Kabe verfasserin aut Atsushi Matsuda verfasserin aut Minoru Kitago verfasserin aut Sachiko Matsuda verfasserin aut Miwa Hirai verfasserin aut Tomomi Nakagawa verfasserin aut Yohei Masugi verfasserin aut Takako Hishiki verfasserin aut Yuki Nakamura verfasserin aut Masahiro Shinoda verfasserin aut Hiroshi Yagi verfasserin aut Yuta Abe verfasserin aut Go Oshima verfasserin aut Shutaro Hori verfasserin aut Yutaka Nakano verfasserin aut Kazufumi Honda verfasserin aut Ayumi Kashiro verfasserin aut Chigusa Morizane verfasserin aut Satoshi Nara verfasserin aut Shojiro Kikuchi verfasserin aut Takahiko Shibahara verfasserin aut Makoto Itonaga verfasserin aut Masayuki Ono verfasserin aut Naoko Minegishi verfasserin aut Seizo Koshiba verfasserin aut Masayuki Yamamoto verfasserin aut Atsushi Kuno verfasserin aut Hiroshi Handa verfasserin aut Michiie Sakamoto verfasserin aut Makoto Suematsu verfasserin aut Yuko Kitagawa verfasserin aut In Cancers MDPI AG, 2010 12(2020), 9, p 2469 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:12 year:2020 number:9, p 2469 https://doi.org/10.3390/cancers12092469 kostenfrei https://doaj.org/article/002f3f7d7400416893ba4df7bfef8829 kostenfrei https://www.mdpi.com/2072-6694/12/9/2469 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020 9, p 2469
allfieldsGer	10.3390/cancers12092469 doi (DE-627)DOAJ041581040 (DE-599)DOAJ002f3f7d7400416893ba4df7bfef8829 DE-627 ger DE-627 rakwb eng RC254-282 Takahiro Yokose verfasserin aut <i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling of extracellular vesicles (EVs) derived from serum (two cohorts including 117 PC patients and 98 normal controls) using lectin microarray. The glyco-candidates of PC-specific EVs were quantified using a high-sensitive exosome-counting system, ExoCounter. An absolute quantification system for altered glycan-containing EVs elevated in PC serum was established. EVs recognized by <i<O</i<-glycan-binding lectins ABA or ACA were identified as candidate markers by lectin microarray. Quantitative analyses using ExoCounter revealed that the ABA- or ACA-positive EVs were significantly increased in the culture of PC cell lines or in the serum of PC patients including carbohydrate antigen 19-9 negative patients with high area under curve values. The elevated numbers of EVs in PC serum returned to normal levels after pancreatectomy. Histological examination confirmed that the tumors stained with ABA/ACA. These specific EVs with <i<O</i<-glycans recognized by ABA/ACA are elevated in PC sera and can act as potential biomarkers in a liquid biopsy for PC patients screening. extracellular vesicles lectin microarray pancreatic cancer liquid biopsy <i<O</i<-glycan glycomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yasuaki Kabe verfasserin aut Atsushi Matsuda verfasserin aut Minoru Kitago verfasserin aut Sachiko Matsuda verfasserin aut Miwa Hirai verfasserin aut Tomomi Nakagawa verfasserin aut Yohei Masugi verfasserin aut Takako Hishiki verfasserin aut Yuki Nakamura verfasserin aut Masahiro Shinoda verfasserin aut Hiroshi Yagi verfasserin aut Yuta Abe verfasserin aut Go Oshima verfasserin aut Shutaro Hori verfasserin aut Yutaka Nakano verfasserin aut Kazufumi Honda verfasserin aut Ayumi Kashiro verfasserin aut Chigusa Morizane verfasserin aut Satoshi Nara verfasserin aut Shojiro Kikuchi verfasserin aut Takahiko Shibahara verfasserin aut Makoto Itonaga verfasserin aut Masayuki Ono verfasserin aut Naoko Minegishi verfasserin aut Seizo Koshiba verfasserin aut Masayuki Yamamoto verfasserin aut Atsushi Kuno verfasserin aut Hiroshi Handa verfasserin aut Michiie Sakamoto verfasserin aut Makoto Suematsu verfasserin aut Yuko Kitagawa verfasserin aut In Cancers MDPI AG, 2010 12(2020), 9, p 2469 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:12 year:2020 number:9, p 2469 https://doi.org/10.3390/cancers12092469 kostenfrei https://doaj.org/article/002f3f7d7400416893ba4df7bfef8829 kostenfrei https://www.mdpi.com/2072-6694/12/9/2469 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020 9, p 2469
allfieldsSound	10.3390/cancers12092469 doi (DE-627)DOAJ041581040 (DE-599)DOAJ002f3f7d7400416893ba4df7bfef8829 DE-627 ger DE-627 rakwb eng RC254-282 Takahiro Yokose verfasserin aut <i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling of extracellular vesicles (EVs) derived from serum (two cohorts including 117 PC patients and 98 normal controls) using lectin microarray. The glyco-candidates of PC-specific EVs were quantified using a high-sensitive exosome-counting system, ExoCounter. An absolute quantification system for altered glycan-containing EVs elevated in PC serum was established. EVs recognized by <i<O</i<-glycan-binding lectins ABA or ACA were identified as candidate markers by lectin microarray. Quantitative analyses using ExoCounter revealed that the ABA- or ACA-positive EVs were significantly increased in the culture of PC cell lines or in the serum of PC patients including carbohydrate antigen 19-9 negative patients with high area under curve values. The elevated numbers of EVs in PC serum returned to normal levels after pancreatectomy. Histological examination confirmed that the tumors stained with ABA/ACA. These specific EVs with <i<O</i<-glycans recognized by ABA/ACA are elevated in PC sera and can act as potential biomarkers in a liquid biopsy for PC patients screening. extracellular vesicles lectin microarray pancreatic cancer liquid biopsy <i<O</i<-glycan glycomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yasuaki Kabe verfasserin aut Atsushi Matsuda verfasserin aut Minoru Kitago verfasserin aut Sachiko Matsuda verfasserin aut Miwa Hirai verfasserin aut Tomomi Nakagawa verfasserin aut Yohei Masugi verfasserin aut Takako Hishiki verfasserin aut Yuki Nakamura verfasserin aut Masahiro Shinoda verfasserin aut Hiroshi Yagi verfasserin aut Yuta Abe verfasserin aut Go Oshima verfasserin aut Shutaro Hori verfasserin aut Yutaka Nakano verfasserin aut Kazufumi Honda verfasserin aut Ayumi Kashiro verfasserin aut Chigusa Morizane verfasserin aut Satoshi Nara verfasserin aut Shojiro Kikuchi verfasserin aut Takahiko Shibahara verfasserin aut Makoto Itonaga verfasserin aut Masayuki Ono verfasserin aut Naoko Minegishi verfasserin aut Seizo Koshiba verfasserin aut Masayuki Yamamoto verfasserin aut Atsushi Kuno verfasserin aut Hiroshi Handa verfasserin aut Michiie Sakamoto verfasserin aut Makoto Suematsu verfasserin aut Yuko Kitagawa verfasserin aut In Cancers MDPI AG, 2010 12(2020), 9, p 2469 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:12 year:2020 number:9, p 2469 https://doi.org/10.3390/cancers12092469 kostenfrei https://doaj.org/article/002f3f7d7400416893ba4df7bfef8829 kostenfrei https://www.mdpi.com/2072-6694/12/9/2469 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020 9, p 2469
language	English
source	In Cancers 12(2020), 9, p 2469 volume:12 year:2020 number:9, p 2469
sourceStr	In Cancers 12(2020), 9, p 2469 volume:12 year:2020 number:9, p 2469
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	extracellular vesicles lectin microarray pancreatic cancer liquid biopsy <i<O</i<-glycan glycomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Cancers
authorswithroles_txt_mv	Takahiro Yokose @@aut@@ Yasuaki Kabe @@aut@@ Atsushi Matsuda @@aut@@ Minoru Kitago @@aut@@ Sachiko Matsuda @@aut@@ Miwa Hirai @@aut@@ Tomomi Nakagawa @@aut@@ Yohei Masugi @@aut@@ Takako Hishiki @@aut@@ Yuki Nakamura @@aut@@ Masahiro Shinoda @@aut@@ Hiroshi Yagi @@aut@@ Yuta Abe @@aut@@ Go Oshima @@aut@@ Shutaro Hori @@aut@@ Yutaka Nakano @@aut@@ Kazufumi Honda @@aut@@ Ayumi Kashiro @@aut@@ Chigusa Morizane @@aut@@ Satoshi Nara @@aut@@ Shojiro Kikuchi @@aut@@ Takahiko Shibahara @@aut@@ Makoto Itonaga @@aut@@ Masayuki Ono @@aut@@ Naoko Minegishi @@aut@@ Seizo Koshiba @@aut@@ Masayuki Yamamoto @@aut@@ Atsushi Kuno @@aut@@ Hiroshi Handa @@aut@@ Michiie Sakamoto @@aut@@ Makoto Suematsu @@aut@@ Yuko Kitagawa @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	614095670
id	DOAJ041581040
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ041581040</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412214526.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers12092469</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ041581040</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ002f3f7d7400416893ba4df7bfef8829</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Takahiro Yokose</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a"><i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling of extracellular vesicles (EVs) derived from serum (two cohorts including 117 PC patients and 98 normal controls) using lectin microarray. The glyco-candidates of PC-specific EVs were quantified using a high-sensitive exosome-counting system, ExoCounter. An absolute quantification system for altered glycan-containing EVs elevated in PC serum was established. EVs recognized by <i<O</i<-glycan-binding lectins ABA or ACA were identified as candidate markers by lectin microarray. Quantitative analyses using ExoCounter revealed that the ABA- or ACA-positive EVs were significantly increased in the culture of PC cell lines or in the serum of PC patients including carbohydrate antigen 19-9 negative patients with high area under curve values. The elevated numbers of EVs in PC serum returned to normal levels after pancreatectomy. Histological examination confirmed that the tumors stained with ABA/ACA. These specific EVs with <i<O</i<-glycans recognized by ABA/ACA are elevated in PC sera and can act as potential biomarkers in a liquid biopsy for PC patients screening.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">extracellular vesicles</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lectin microarray</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pancreatic cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">liquid biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<O</i<-glycan</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">glycomics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yasuaki Kabe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Atsushi Matsuda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Minoru Kitago</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sachiko Matsuda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miwa Hirai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomomi Nakagawa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yohei Masugi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takako Hishiki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuki Nakamura</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masahiro Shinoda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Yagi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuta Abe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Go Oshima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shutaro Hori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yutaka Nakano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kazufumi Honda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ayumi Kashiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chigusa Morizane</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Satoshi Nara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shojiro Kikuchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takahiko Shibahara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Makoto Itonaga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masayuki Ono</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Naoko Minegishi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Seizo Koshiba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masayuki Yamamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Atsushi Kuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Handa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michiie Sakamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Makoto Suematsu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuko Kitagawa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">12(2020), 9, p 2469</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:9, p 2469</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers12092469</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/002f3f7d7400416893ba4df7bfef8829</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/12/9/2469</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2020</subfield><subfield code="e">9, p 2469</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Takahiro Yokose
spellingShingle	Takahiro Yokose misc RC254-282 misc extracellular vesicles misc lectin microarray misc pancreatic cancer misc liquid biopsy misc <i<O</i<-glycan misc glycomics misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens <i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer
authorStr	Takahiro Yokose
ppnlink_with_tag_str_mv	@@773@@(DE-627)614095670
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	20726694
topic_title	RC254-282 <i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer extracellular vesicles lectin microarray pancreatic cancer liquid biopsy <i<O</i<-glycan glycomics
topic	misc RC254-282 misc extracellular vesicles misc lectin microarray misc pancreatic cancer misc liquid biopsy misc <i<O</i<-glycan misc glycomics misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc extracellular vesicles misc lectin microarray misc pancreatic cancer misc liquid biopsy misc <i<O</i<-glycan misc glycomics misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc extracellular vesicles misc lectin microarray misc pancreatic cancer misc liquid biopsy misc <i<O</i<-glycan misc glycomics misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Cancers
hierarchy_parent_id	614095670
hierarchy_top_title	Cancers
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)614095670 (DE-600)2527080-1
title	<i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer
ctrlnum	(DE-627)DOAJ041581040 (DE-599)DOAJ002f3f7d7400416893ba4df7bfef8829
title_full	<i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer
author_sort	Takahiro Yokose
journal	Cancers
journalStr	Cancers
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
author_browse	Takahiro Yokose Yasuaki Kabe Atsushi Matsuda Minoru Kitago Sachiko Matsuda Miwa Hirai Tomomi Nakagawa Yohei Masugi Takako Hishiki Yuki Nakamura Masahiro Shinoda Hiroshi Yagi Yuta Abe Go Oshima Shutaro Hori Yutaka Nakano Kazufumi Honda Ayumi Kashiro Chigusa Morizane Satoshi Nara Shojiro Kikuchi Takahiko Shibahara Makoto Itonaga Masayuki Ono Naoko Minegishi Seizo Koshiba Masayuki Yamamoto Atsushi Kuno Hiroshi Handa Michiie Sakamoto Makoto Suematsu Yuko Kitagawa
container_volume	12
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Takahiro Yokose
doi_str_mv	10.3390/cancers12092469
author2-role	verfasserin
title_sort	<i<o</i<-glycan-altered extracellular vesicles: a specific serum marker elevated in pancreatic cancer
callnumber	RC254-282
title_auth	<i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer
abstract	Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling of extracellular vesicles (EVs) derived from serum (two cohorts including 117 PC patients and 98 normal controls) using lectin microarray. The glyco-candidates of PC-specific EVs were quantified using a high-sensitive exosome-counting system, ExoCounter. An absolute quantification system for altered glycan-containing EVs elevated in PC serum was established. EVs recognized by <i<O</i<-glycan-binding lectins ABA or ACA were identified as candidate markers by lectin microarray. Quantitative analyses using ExoCounter revealed that the ABA- or ACA-positive EVs were significantly increased in the culture of PC cell lines or in the serum of PC patients including carbohydrate antigen 19-9 negative patients with high area under curve values. The elevated numbers of EVs in PC serum returned to normal levels after pancreatectomy. Histological examination confirmed that the tumors stained with ABA/ACA. These specific EVs with <i<O</i<-glycans recognized by ABA/ACA are elevated in PC sera and can act as potential biomarkers in a liquid biopsy for PC patients screening.
abstractGer	Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling of extracellular vesicles (EVs) derived from serum (two cohorts including 117 PC patients and 98 normal controls) using lectin microarray. The glyco-candidates of PC-specific EVs were quantified using a high-sensitive exosome-counting system, ExoCounter. An absolute quantification system for altered glycan-containing EVs elevated in PC serum was established. EVs recognized by <i<O</i<-glycan-binding lectins ABA or ACA were identified as candidate markers by lectin microarray. Quantitative analyses using ExoCounter revealed that the ABA- or ACA-positive EVs were significantly increased in the culture of PC cell lines or in the serum of PC patients including carbohydrate antigen 19-9 negative patients with high area under curve values. The elevated numbers of EVs in PC serum returned to normal levels after pancreatectomy. Histological examination confirmed that the tumors stained with ABA/ACA. These specific EVs with <i<O</i<-glycans recognized by ABA/ACA are elevated in PC sera and can act as potential biomarkers in a liquid biopsy for PC patients screening.
abstract_unstemmed	Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling of extracellular vesicles (EVs) derived from serum (two cohorts including 117 PC patients and 98 normal controls) using lectin microarray. The glyco-candidates of PC-specific EVs were quantified using a high-sensitive exosome-counting system, ExoCounter. An absolute quantification system for altered glycan-containing EVs elevated in PC serum was established. EVs recognized by <i<O</i<-glycan-binding lectins ABA or ACA were identified as candidate markers by lectin microarray. Quantitative analyses using ExoCounter revealed that the ABA- or ACA-positive EVs were significantly increased in the culture of PC cell lines or in the serum of PC patients including carbohydrate antigen 19-9 negative patients with high area under curve values. The elevated numbers of EVs in PC serum returned to normal levels after pancreatectomy. Histological examination confirmed that the tumors stained with ABA/ACA. These specific EVs with <i<O</i<-glycans recognized by ABA/ACA are elevated in PC sera and can act as potential biomarkers in a liquid biopsy for PC patients screening.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	9, p 2469
title_short	<i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer
url	https://doi.org/10.3390/cancers12092469 https://doaj.org/article/002f3f7d7400416893ba4df7bfef8829 https://www.mdpi.com/2072-6694/12/9/2469 https://doaj.org/toc/2072-6694
remote_bool	true
author2	Yasuaki Kabe Atsushi Matsuda Minoru Kitago Sachiko Matsuda Miwa Hirai Tomomi Nakagawa Yohei Masugi Takako Hishiki Yuki Nakamura Masahiro Shinoda Hiroshi Yagi Yuta Abe Go Oshima Shutaro Hori Yutaka Nakano Kazufumi Honda Ayumi Kashiro Chigusa Morizane Satoshi Nara Shojiro Kikuchi Takahiko Shibahara Makoto Itonaga Masayuki Ono Naoko Minegishi Seizo Koshiba Masayuki Yamamoto Atsushi Kuno Hiroshi Handa Michiie Sakamoto Makoto Suematsu Yuko Kitagawa
author2Str	Yasuaki Kabe Atsushi Matsuda Minoru Kitago Sachiko Matsuda Miwa Hirai Tomomi Nakagawa Yohei Masugi Takako Hishiki Yuki Nakamura Masahiro Shinoda Hiroshi Yagi Yuta Abe Go Oshima Shutaro Hori Yutaka Nakano Kazufumi Honda Ayumi Kashiro Chigusa Morizane Satoshi Nara Shojiro Kikuchi Takahiko Shibahara Makoto Itonaga Masayuki Ono Naoko Minegishi Seizo Koshiba Masayuki Yamamoto Atsushi Kuno Hiroshi Handa Michiie Sakamoto Makoto Suematsu Yuko Kitagawa
ppnlink	614095670
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/cancers12092469
callnumber-a	RC254-282
up_date	2024-07-03T21:01:47.782Z
_version_	1803593195492212736
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ041581040</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412214526.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers12092469</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ041581040</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ002f3f7d7400416893ba4df7bfef8829</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Takahiro Yokose</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a"><i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pancreatic cancer (PC) is among the most lethal malignancies due to an often delayed and difficult initial diagnosis. Therefore, the development of a novel, early stage, diagnostic PC marker in liquid biopsies is of great significance. In this study, we analyzed the differential glycomic profiling of extracellular vesicles (EVs) derived from serum (two cohorts including 117 PC patients and 98 normal controls) using lectin microarray. The glyco-candidates of PC-specific EVs were quantified using a high-sensitive exosome-counting system, ExoCounter. An absolute quantification system for altered glycan-containing EVs elevated in PC serum was established. EVs recognized by <i<O</i<-glycan-binding lectins ABA or ACA were identified as candidate markers by lectin microarray. Quantitative analyses using ExoCounter revealed that the ABA- or ACA-positive EVs were significantly increased in the culture of PC cell lines or in the serum of PC patients including carbohydrate antigen 19-9 negative patients with high area under curve values. The elevated numbers of EVs in PC serum returned to normal levels after pancreatectomy. Histological examination confirmed that the tumors stained with ABA/ACA. These specific EVs with <i<O</i<-glycans recognized by ABA/ACA are elevated in PC sera and can act as potential biomarkers in a liquid biopsy for PC patients screening.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">extracellular vesicles</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lectin microarray</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pancreatic cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">liquid biopsy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<O</i<-glycan</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">glycomics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yasuaki Kabe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Atsushi Matsuda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Minoru Kitago</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sachiko Matsuda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miwa Hirai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomomi Nakagawa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yohei Masugi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takako Hishiki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuki Nakamura</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masahiro Shinoda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Yagi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuta Abe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Go Oshima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shutaro Hori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yutaka Nakano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kazufumi Honda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ayumi Kashiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chigusa Morizane</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Satoshi Nara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shojiro Kikuchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takahiko Shibahara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Makoto Itonaga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masayuki Ono</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Naoko Minegishi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Seizo Koshiba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masayuki Yamamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Atsushi Kuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Handa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michiie Sakamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Makoto Suematsu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuko Kitagawa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">12(2020), 9, p 2469</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:9, p 2469</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers12092469</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/002f3f7d7400416893ba4df7bfef8829</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/12/9/2469</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2020</subfield><subfield code="e">9, p 2469</subfield></datafield></record></collection>
score	7.4000044

Nicht das Richtige dabei?

Schreiben Sie uns!

<i<O</i<-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?